Table of Contents
Overview
Definition of Tumor Biology
Tumor biology, also known as cancer biology, is a multidisciplinary field focused on understanding the complex biological processes involved in cancer development, progression, and treatment.[4.1] This field examines key aspects such as the genetic and epigenetic alterations that initiate cancer, the specific cells affected, and the mechanisms of invasion and metastasis that influence tumor aggressiveness.[3.1] These alterations are crucial as they lead to cell transformation and can result in the spread of cancer to other tissues, making their study essential for developing effective treatment strategies and improving patient outcomes in cancer care.[3.1][4.1] Cancer is characterized as a group of more than 100 diseases that arise from the uncontrolled division of the body's cells over time.[5.1] The study of tumor biology includes examining tumor suppressor genes, which are crucial in regulating cell growth and preventing cancer development.[4.1] Additionally, it investigates the genomic aspects of cancer, focusing on the complete sequence of DNA and its expression in tumor cells, which are critical for understanding the mechanisms of carcinogenesis.[3.1]Importance of Tumor Biology Research
Research in tumor biology is crucial for understanding the complex mechanisms that drive cancer development and progression. Cancer is characterized as a group of heterogeneous diseases resulting from genetic alterations, epigenetic changes, and environmental stimuli that enhance cancer cell plasticity.[21.1] The interactions between genetic and epigenetic factors play a critical role in carcinogenesis and cancer progression, influencing uncontrolled proliferation, tumor heterogeneity, and metastasis.[17.1] Additionally, the interplay between these alterations adds another layer of complexity, as how they interact and influence each other significantly shapes the tumor landscape and response to therapy.[20.1] This complexity highlights the necessity of exploring these interactions to inform the development of effective personalized cancer treatments. Research in tumor biology has significantly influenced the development of targeted therapies, which are designed to specifically target the genetic changes or mutations that transform healthy cells into cancerous ones. These therapies, such as lapatinib for breast cancer, crizotinib for lung cancer, bevacizumab for lung and colon cancer, and sorafenib for liver and kidney cancer, exemplify how insights from tumor biology can lead to more effective treatment options with fewer side effects compared to traditional chemotherapy.[15.1] Targeted therapies are particularly advantageous as they selectively kill cancer cells while sparing healthy cells, thereby minimizing collateral damage.[16.1] Furthermore, the emergence of histology-independent therapies (HITs), which can treat any type of cancer that possesses a specific genetic alteration, underscores the innovative potential of tumor biology research. Notable examples of HITs include larotrectinib and entrectinib, which highlight the shift towards more personalized cancer treatment strategies.[14.1] As the number of targeted therapy drugs approved by the Food and Drug Administration (FDA) continues to grow, the role of tumor biology in shaping cancer treatment remains increasingly vital.[16.1] Understanding the genetic and epigenetic heterogeneity of tumors is crucial for the development of personalized cancer therapies. A complete understanding of these alterations may assist in designing combinations of targeted therapies based on molecular information extracted from individual tumors.[22.1] One significant aspect of epigenetic cancer research is the potential to reactivate epigenetically inactivated genes with appropriate drugs, which contrasts with genetic changes that are irreversible.[19.1] This distinction highlights the importance of integrating both genetic and epigenetic insights to address the complexities of tumor biology and improve therapeutic strategies.History
Key Milestones in Cancer Research
The field of tumor biology has undergone significant evolution since its inception, marked by several key milestones that have shaped our understanding of cancer. One of the earliest recorded instances of tumors in humans dates back to around 3000 B.C., as documented in an Egyptian papyrus by Edwin Smith, which described a case of breast cancer and its surgical treatment.[43.1] This historical context laid the groundwork for future explorations into the nature of tumors. A pivotal moment in cancer research occurred in 1911 when Peyton Rous discovered the Rous sarcoma virus (RSV), which was shown to induce tumors in chickens. This groundbreaking finding challenged existing paradigms by suggesting that some cancers could be caused by infectious agents, leading to the hypothesis that similar mechanisms might exist in other organisms.[53.1] Rous's work initiated the study of tumor virology and contributed to the identification of oncogenes, which are genes that promote cancer growth.[50.1] Despite initial skepticism from the scientific community, Rous's discovery has been recognized as a seminal event in 20th-century biology, fundamentally altering the landscape of oncology and virology.[52.1] As research progressed, the understanding of tumor evolution began to incorporate concepts from evolutionary biology. Current investigations reflect earlier debates regarding the role of non-Darwinian mechanisms and the dynamics of life history in cancer evolution, particularly the trade-off between proliferation and metastasis.[42.1] These discussions underscore the complexity of cancer biology and the multifaceted nature of tumor development. In recent decades, significant advancements in cancer treatment have been marked by the FDA's approval of several key therapies. Notably, tamoxifen, an antiestrogen drug originally developed for birth control, was approved for the treatment of breast cancer. Additionally, trastuzumab, a monoclonal antibody targeting HER2-positive metastatic breast cancer, and sipuleucel-T, a cancer treatment vaccine utilizing a patient's own immune cells for metastatic prostate cancer, have also received FDA approval.[60.1] The resurgence of oncolytic viruses as a viable cancer treatment modality was highlighted by the approval of T-VEC in 2015 for melanoma and Delytact in 2021 for malignant glioma.[62.1] Furthermore, the 2020s have seen the FDA's approval of Sotorasib, the first small molecule inhibitor specifically targeting KRAS gene mutations, and the National Comprehensive Cancer Network's recommendation of the combination of atezolizumab and bevacizumab as the preferred first-line treatment for hepatocellular carcinoma.[62.1] These developments reflect the ongoing evolution of cancer treatment strategies and the continuous efforts to improve patient outcomes.[60.1]Evolution of Cancer Treatment Approaches
The evolution of cancer treatment approaches has been significantly influenced by advancements in our understanding of tumor biology. Initially, cancer treatments were largely non-specific, utilizing cytotoxic drugs that indiscriminately damaged both tumor and normal cells. Over time, there has been a notable shift towards more targeted therapies and immunotherapy approaches, which are designed to specifically target unique molecular features of cancer cells while minimizing harm to healthy tissues.[63.1] This transition has been facilitated by the identification of cancer biomarkers, which have transformed oncology by enabling treatments tailored to the unique profiles of individual tumors. The progress in understanding cancer biology, along with advancements in testing methods and insights into the immune microenvironment, has propelled the field of precision oncology, leading to improved patient outcomes.[58.1] Moreover, the development of companion diagnostics (CDx) has played a crucial role in identifying which treatments will be most effective for specific patients, further enhancing the efficacy and safety of personalized treatment models.[65.1] Recent innovations, such as novel cell therapies and more accurate tumor models like organoids, have also contributed to this evolution, allowing for targeted interventions that reduce collateral damage to healthy tissues.[65.1] As the field continues to evolve, the integration of biological therapies—including cancer vaccines, monoclonal antibodies, and adoptive cell transfer—has demonstrated significant potential in personalizing cancer treatment and improving response rates and progression-free survival in clinical trials.[64.1] This ongoing evolution reflects a deeper understanding of the complexities of tumor biology and the need for more sophisticated and individualized treatment strategies in the fight against cancer.Recent Advancements
Immunotherapy and Checkpoint Inhibitors
Immunotherapy has significantly transformed the landscape of cancer treatment, particularly through the development and application of immune checkpoint inhibitors (ICIs). These therapies aim to enhance the body's immune response against tumors by targeting specific pathways that tumors exploit to evade immune detection. The primary goal of cancer immunotherapy is to boost or restore the immune system's ability to recognize and destroy cancer cells, effectively shifting the balance back in favor of immune protection.[93.1] The introduction of ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, has marked a paradigm shift in the treatment of various malignancies, including melanoma, non-small-cell lung cancer, and lymphoma. Initially, these agents were used as single-agent therapies; however, recent trends indicate a growing preference for combination approaches. By employing multiple ICIs or integrating them with other therapeutic modalities—such as chemotherapy, radiotherapy, and other immunotherapeutics—clinicians have observed enhanced response rates and improved clinical outcomes.[95.1] This strategy leverages the non-redundant mechanisms of action of the individual agents, thereby maximizing therapeutic efficacy.[95.1] Recent advancements in immunotherapy have also highlighted the importance of precision medicine, which utilizes molecular biology to identify specific genetic markers for more accurate prognoses and targeted therapies. This integration of biomarkers into clinical practice allows for more personalized treatment strategies, significantly improving the management of cancer.[92.1] Furthermore, ongoing research is exploring innovative combination therapies that incorporate ICIs with chimeric antigen receptor (CAR) T-cell therapy and strategies to modulate the tumor microenvironment, thereby enhancing immune cell infiltration and function.[89.1]Emerging Research Areas: Exosomes and Microbiome
Emerging research areas in tumor biology have increasingly focused on the roles of exosomes and the microbiome in cancer progression and treatment. The mechanisms involved in immune responses to cancer have been extensively studied for several decades, with considerable attention paid to harnessing the immune system's therapeutic potential. Cancer immunotherapy has established itself as a promising new treatment option for a variety of cancer types, utilizing various strategies including cancer vaccines and monoclonal antibodies.[79.1] This approach aims to enhance the innate immune response to target tumor cells, distinguishing it from traditional therapies that directly eliminate cancer cells.[79.1] Recent advancements in tumor biology have significantly transformed cancer treatment strategies. The approval of oncolytic viruses, such as T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, has underscored the resurgence of innovative cancer treatment modalities.[81.1] The 2020s have further witnessed the FDA's approval of Sotorasib, the first small molecule inhibitor specifically targeting KRAS gene mutations, reflecting the ongoing evolution in cancer therapeutics.[81.1] Additionally, the National Comprehensive Cancer Network (NCCN) guidelines from 2021 have identified the combination of atezolizumab and bevacizumab as the preferred first-line treatment for patients with hepatocellular carcinoma (HCC), highlighting the critical role of immunotherapy and anti-angiogenic therapy in managing this aggressive cancer type.[81.1] Moreover, significant progress has been made in the exploration and discovery of novel tumor biomarkers, which has greatly advanced personalized medicine and improved outcomes for cancer patients.[82.1] Over the past decades, several PCR assays approved by the FDA have been utilized for diagnosing KRAS mutation status in formalin-fixed paraffin-embedded tissue, aiding in the guidance of anti-EGFR antibody treatment for metastatic colorectal cancer (CRC).[82.1] Quantitative PCR (qPCR) assays have also proven effective in detecting minimal residual disease (MRD) in leukemia, such as the quantification of BCR-ABL-positive cells following induction chemotherapy or transplantation in acute lymphoblastic leukemia (ALL).[82.1] Furthermore, PCR technology is widely employed to identify abnormal genes and mRNA amplification in tumors, exemplified by MYCN amplification in neuroblastoma, while ligand-targeted PCR is essential for detecting folate receptor-positive circulating tumor cells as potential diagnostic biomarkers in pancreatic cancer.[82.1]In this section:
Mechanisms Of Tumorigenesis
Genetic and Epigenetic Alterations
Tumorigenesis is fundamentally influenced by genetic and epigenetic alterations that drive the transformation of normal cells into cancerous ones. The initial event in this multistep process is the acquisition of oncogenic mutations, which confer a clonal advantage to normal cells. Despite the presence of pervasive somatic mutations and clonal expansion in normal tissues, the transformation into cancer remains a rare occurrence, suggesting that additional factors are necessary for tumorigenesis to proceed.[105.1] The identification of key cancer-related genes has evolved significantly since the early 1980s, when the first proto-oncogene, RAS, and the tumor suppressor gene, RB1, were cloned. This period marked the beginning of a broader understanding of cancer genetics, leading to the discovery of various genetic alterations, including copy number variations, translocations, and promoter hypermethylation. The advent of next-generation sequencing in the mid-2000s further accelerated cancer genomics, culminating in large-scale initiatives such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). These efforts have greatly expanded our understanding of the genetic landscape of cancer, revealing that mutations can be classified as either driver mutations, which contribute to cancer progression, or passenger mutations, which do not.[106.1] The transition from an inflammatory process to tumorigenesis is a complex phenomenon that has garnered significant scientific interest. The identities of transformed cells result from the combined influence of intrinsic genetic and epigenetic profiles, along with external signaling that activates oncogenic pathways and remodels the microenvironment.[107.1] While the mechanisms underlying inflammation induced by environmental agents are well understood, the oncogenic changes that follow a chronic inflammatory state in the tissue microenvironment, which can lead to pro-tumorigenic processes, remain less well characterized.[108.1] This intricate interplay highlights the importance of both genetic and environmental factors in the early stages of tumorigenesis. Specific oncogenic mutations, particularly in the RAS gene, are among the most common alterations found in human cancers and significantly contribute to tumor onset and progression.[110.1] These mutations enhance the oncogenic potential of cells by influencing critical signaling pathways, including the RTK/RAS/MAP-Kinase pathway and the PI3K/Akt signaling pathway.[113.1] Additionally, RAS mutations are key oncogenic drivers and therapeutic targets, as they can influence cellular behaviors such as migration and invasion, which are critical for the metastatic potential of tumors.[111.1] By affecting these pathways, RAS mutations complicate therapeutic interventions aimed at treating cancers.[110.1] The integration of genetic profiling into clinical practice signifies a transformative shift towards personalized medicine, which moves away from a traditional one-size-fits-all approach to a more individualized model of care. By tailoring healthcare to the unique genetic makeup of each patient, personalized medicine holds the promise of more effective, targeted, and precise interventions, ultimately improving patient outcomes.[117.1] This approach not only considers a patient’s genetic profile but also incorporates lifestyle and environmental factors to create customized treatment plans, offering new hope for patients with rare genetic disorders.[114.1] However, the implementation of personalized medicine in standard clinical practice presents several challenges. These include the necessity for extensive education of healthcare providers, concerns regarding genetic data privacy, and the high costs associated with genetic testing and analysis.[115.1] Additionally, ethical considerations such as genetic discrimination and the equitable distribution of resources must be addressed to ensure the responsible use of genetic information.[116.1] By navigating these advancements and challenges, personalized medicine has the potential to revolutionize healthcare, providing tailored and effective treatments based on individuals' unique genetic characteristics.[116.1]Role of Tumor Microenvironment
The tumor microenvironment (TME) is a complex ecosystem that plays a crucial role in cancer progression and therapy response. It consists of various non-malignant cells, including immune cells, fibroblasts, and endothelial cells, as well as the extracellular matrix. These components interact dynamically with cancer cells, influencing tumorigenesis through intricate crosstalk, particularly between cancer cells and immune cells within the TME.[118.1] Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immune cells that significantly contribute to the establishment of an immunosuppressive TME. They facilitate immune evasion, promote tumor growth, and are implicated in treatment resistance across various malignancies, including lung, ovarian, endometrial, and liver cancers.[119.1] The composition of the TME varies among different tumor types, but it consistently includes immune cells, stromal cells, blood vessels, and extracellular matrix components. This composition is not merely passive; rather, it actively promotes cancer progression.[121.1] Chronic inflammation is another critical aspect of the TME that influences cancer development. It can enhance tumor growth by providing bioactive molecules such as cytokines, growth factors, and chemokines, which maintain a sustained proliferative rate and promote cell survival while also inducing angiogenesis.[140.1] The relationship between immune cells and the TME is complex, as these immune cells can either suppress or promote tumor growth depending on the context.[122.1] Recent advances in understanding the TME have highlighted its role in modulating cancer therapies. For instance, tumor cell-targeting and TME-responsive nanoplatforms are being developed for multimodal treatment approaches, such as photodynamic and chemodynamic therapies.[120.1] This underscores the importance of the TME in shaping therapeutic strategies and the need for further research to exploit these interactions for improved cancer treatment outcomes.In this section:
Cancer Genomics
Genomic Sequencing and Analysis
The rapid development of next-generation sequencing (NGS) approaches over the last decade has significantly transformed the landscape of cancer genomics, allowing researchers to assess multiple genes simultaneously.[149.1] Initially, the mission of cancer genomics was to identify all cancer driver genes, primarily utilizing NGS-based technologies. This field has evolved from focusing on a limited number of genes or tumors to conducting large-scale, whole-genome, multi-omics, and pan-cancer analyses, as exemplified by initiatives like The Cancer Genome Atlas (TCGA).[150.1] By characterizing not only the DNA but also gene expression, proteins, and various other molecular features of cancer, researchers can identify key changes that may lead to the disease.[151.1] This comprehensive understanding of genetic and epigenetic alterations is crucial, as cancer begins with these changes occurring in specific cells, which can spread and migrate to other tissues.[152.1] Ultimately, the insights gained from cancer genomics are paving the way for precision medicine, where treatment strategies are tailored to the unique genetic profile of a patient's tumor.[151.1] Recent advancements in cancer genomics are significantly enhancing our understanding of tumor biology and the underlying genetic alterations associated with cancer. Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics, particularly through the identification of driver gene alterations such as mutations and copy number variations.[153.1] The integration of cancer genomic data with electronic health record (EHR) systems is crucial for guiding clinical decision-making, supporting secondary uses of data, and ultimately improving patient care in oncology clinics.[154.1] Furthermore, genomic biomarkers play a vital role in therapeutic selection for patients with advanced solid tumors, as they inform the interpretation and integration of molecular profiling into clinical decision-making processes.[155.1] Programs that utilize patient-matched clinicogenomic data, along with spatial single-cell proteomics analysis, are instrumental in supporting profiling-driven decision-making for cancer patients, exemplified by initiatives like the Molecular Tumor Board.[156.1] Advancements in genomic sequencing, particularly through large-scale initiatives like The Cancer Genome Atlas (TCGA), have profoundly influenced cancer research and treatment. The TCGA project has fundamentally reshaped our understanding of cancer at a molecular level, expediting the discovery of new drivers, pathways, and hallmarks of cancer biology, as well as novel drug targets.[161.1] For example, an integrated analysis of genetic alterations in over 9,000 tumors profiled by TCGA has highlighted significant actionable alterations in key signaling pathways, suggesting opportunities for targeted and combination therapies.[162.1] Furthermore, researchers have identified 776 genomic alterations linked to survival outcomes across 20 cancer types, demonstrating the potential of integrating detailed somatic mutation profiling with treatment and outcomes data.[157.1] Despite these advancements, challenges remain in the clinical implementation of genomic data, including the need for the development of tools and infrastructures to support pharmacogenomics-informed pharmacotherapy, which tailors drug selection and dosing to patients' genetic features.[158.1] As the field progresses, it is essential to address these challenges to move towards the realization of personalized cancer medicine in clinical practice.[160.1]Implications for Personalized Medicine
The integration of cancer genomics into clinical practice is revolutionizing personalized medicine by enhancing treatment decision-making and improving patient outcomes. The seamless incorporation of genomic data with electronic health record (EHR) systems is pivotal for guiding clinical decisions and optimizing patient care in oncology settings.[154.1] Genomic biomarkers are instrumental in selecting therapies for patients with advanced solid tumors, offering insights into the molecular characteristics of tumors to inform treatment strategies.[155.1] Innovative programs, such as those at the Molecular Tumor Board, utilize patient-specific clinicogenomic data and spatial single-cell proteomics to support precision-driven decision-making for cancer patients.[156.1] This approach is bolstered by research identifying genomic alterations linked to survival outcomes across various cancer types, facilitating the selection of specific immunotherapies, chemotherapies, or targeted therapies.[157.1] Large-scale studies like The Cancer Genome Atlas (TCGA) have significantly influenced the development of targeted therapies, expediting the discovery of new cancer drivers and pathways.[159.1] Identifying mutations in genes such as TP53 and BRCA has enabled more precise therapies, potentially enhancing patient outcomes.[161.1] Integrated analyses of genetic alterations in signaling pathways have revealed actionable targets, suggesting opportunities for targeted and combination therapies.[162.1] Despite these advancements, challenges persist in translating genetic discoveries into therapeutic applications. Ongoing research is essential to overcome these hurdles.[163.1] Understanding the tumor microenvironment (TME) and its interactions with cancer cells is crucial for developing effective therapies. The TME's complexity affects cancer progression and therapeutic responses, prompting exploration of innovative strategies targeting the TME to improve treatment outcomes.[165.1] The tumor microenvironment, comprising stromal cells and extracellular matrix components, plays a vital role in cancer progression and metastasis. These interactions contribute to cancer cell heterogeneity and multidrug resistance.[164.1] Somatic gene mutations can elicit adaptive immunity and influence the tumor immune microenvironment, impacting antitumor immunity processes.[166.1] Understanding these cellular and molecular mechanisms can lead to novel strategies to disrupt cancer cell interactions and develop effective therapeutic approaches.[164.1]In this section:
Treatment Strategies
Novel Therapeutic Modalities: Targeted Therapy and Gene Therapy
Recent advancements in cancer treatment have led to the emergence of novel therapeutic modalities, particularly targeted therapy and gene therapy, which aim to improve treatment efficacy and minimize side effects. Targeted therapies have gained prominence due to their ability to specifically inhibit molecular targets associated with cancer, thereby reducing the systemic toxicity often seen with conventional therapies. For instance, small molecule inhibitors such as Gefitinib and Erlotinib have been developed for non-small cell lung cancer, while antibody-drug conjugates (ADCs) utilize antibodies to deliver cytotoxic agents directly to tumor cells, enhancing therapeutic precision.[192.1] Gene therapy is an innovative approach that aims to correct genetic defects or modify gene expression to address cancer. One of the key advancements in this field is the use of next-generation sequencing (NGS), which provides comprehensive cancer profiling. This technology enables clinicians and researchers to gain a deeper understanding of the molecular basis of cancer, allowing for the tailoring of treatment strategies based on specific genomic alterations identified through NGS. Targeted therapies developed from these genomic insights have shown promise in improving patient outcomes across various cancer types, thereby enhancing the effectiveness of treatment modalities.[197.1] The approval of oncolytic viruses, such as T-VEC for melanoma and Delytact for malignant glioma, further exemplifies the evolving landscape of cancer treatment. These therapies harness the ability of viruses to selectively infect and destroy cancer cells while stimulating an immune response against the tumor.[189.1] Moreover, the integration of immunotherapy, particularly immune checkpoint inhibitors, has transformed the treatment paradigm for various malignancies by enhancing the body's immune response to cancer.[196.1]Challenges In Tumor Biology
Societal and Ethical Considerations
Improving patient education is crucial for enhancing understanding of tumor biology and facilitating informed decision-making regarding treatment options. Despite the standard-of-care status of tumor genomic testing (TGT) for patients with advanced or metastatic cancer, patient education prior to TGT is often neglected, highlighting a significant gap in the healthcare process.[227.1] A study demonstrated that a concise four-minute video could effectively educate patients before undergoing TGT, suggesting that innovative educational tools may improve patient comprehension of complex cancer biology.[227.1] The advancements in cancer biomarkers have revolutionized oncology by enabling the development of treatments tailored to the unique profiles of individual tumors. This progress is attributed to a deeper understanding of cancer biology, testing methodologies, and the immune microenvironment, all of which contribute to precision oncology aimed at improving patient outcomes.[228.1] Furthermore, the refined matching of patients to specific treatments is facilitated by an enhanced understanding of the interactions between molecular alterations and the broader genomic context of tumors.[229.1] The historical context of tumor biology research is also significant; for instance, the first whole-genome sequencing of human cancer was conducted in 2008, which has since paved the way for identifying somatic variations in various cancers.[230.1] This foundational work underscores the importance of ongoing research and education in the field. Patient advocacy plays a vital role in the landscape of personalized medicine, particularly in relation to access to clinical trials and experimental therapies. Patients and their advocates engage in various activities to secure specific treatments, reflecting the growing expectation for personalized therapies as part of the patient journey.[246.1] The implications for personalized and precision cancer nursing care include not only the interpretation of genetic testing results but also the provision of advocacy and support throughout the testing process and treatment decision-making.[247.1] Moreover, personalized medicine, characterized by its tailored approach to treatment based on individual patient characteristics, is transforming cancer care. By analyzing biomarkers, healthcare providers can select therapies that specifically target the genetic mutations driving a patient's cancer, thereby enhancing treatment efficacy.[248.1] Companion diagnostics further assist in identifying the most effective treatments for specific tumors, contributing to improved patient outcomes in clinical trials.[249.1]References
[3] Cancer Biology, Epidemiology, and Treatment in the 21st Century ... — Cancer is a disease that begins with genetic and epigenetic alterations occurring in specific cells, some of which can spread and migrate to other tissues.4 Although the biological processes affected in carcinogenesis and the evolution of neoplasms are many and widely different, we will focus on 4 aspects that are particularly relevant in tumor biology: genomic and epigenomic alterations that lead to cell transformation, the cells where these changes occur, and the processes of invasion and metastasis that, to an important degree, determine tumor aggressiveness. The genomics of cancer can be defined as the study of the complete sequence of DNA and its expression in tumor cells. Cancer.
[4] What is cancer biology? - California Learning Resource Network — Cancer biology is a multidisciplinary field of study that aims to understand the complex biological processes involved in the development, progression, and treatment of cancer. ... Key Concepts in Cancer Biology. Tumor Suppressor Genes: Tumor suppressor genes are genes that prevent the development of cancer by regulating cell growth and
[5] Understanding Cancer - NIH Curriculum Supplement Series - NCBI Bookshelf — In simple terms, cancer is a group of more than 100 diseases that develop across time and involve the uncontrolled division of the body's cells. In effect, in familial retinoblastoma, each retinal cell is already primed for tumor development, needing only a second mutational event to trigger the cancerous state. Such tissue-typing tests, when done on cancer cells, reveal that the tumor cells of a particular cancer patient are always of the same transplantation type as the cells of normal tissues located elsewhere in the person's body. Evidence from work with cancer-causing viruses suggested that only a small number of genes were involved, and evidence from cell biology pointed to genes that normally control cell division.
[14] What are targeted cancer drugs? - Cancer Research UK — HITs are a new type of targeted cancer drug. You might also here them called tumour agnostic therapy. HITs are different to other targeted therapies because they treat any type of cancer that has a certain gene change. Most targeted cancer drugs are for a specific cancer type. For example, larotrectinib and entrectinib are the names of 2 HIT drugs.
[15] Targeted Therapy: What It Is, Process & Side Effects - Cleveland Clinic — Targeted therapy is cancer treatment that targets the genetic changes or mutations that turn healthy cells into cancer cells. Targeted therapy helps healthcare providers treat cancer cells without hurting healthy cells. To use targeted therapy, healthcare providers test for the genetic changes responsible for helping cancer cells grow and survive. Targeted therapy helps healthcare providers treat cancer cells without hurting healthy cells. Your healthcare provider will confirm if targeted therapy is the right treatment for the kind of cancer that you have. In targeted therapy, healthcare providers identify cancer cell targets and use drugs tailored to specific cancer cells’ genetic instructions. Targeted therapy is changing how healthcare providers treat cancer. If you have cancer, ask your healthcare provider about targeted therapy.
[16] Targeted Cancer Therapy: Benefits, Risks, and How It Works - Healthline — What Is Targeted Therapy for Cancer? Research shows that, for some types of cancer, target therapies are more effective than chemotherapy drugs and have fewer side effects. The number of targeted therapy drugs approved by the Food and Drug Administration (FDA) for treating various types of cancer continues to grow. Targeted therapy kills only cancer cells, not healthy cells. The effectiveness of targeted therapy depends on factors such as the type of cancer and the specific genetic characteristics of the cancer cells. Targeted therapy uses drugs that kill only mutations in your cancer cells. Targeted cancer therapies. https://www.cancervic.org.au/cancer-information/treatments/treatments-types/targeted-therapy https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies Finding the Best Treatment for NSCLC: Why Mutations MatterLearn about targeted therapy for non-small cell lung cancer.
[17] Cancer Epigenetics: An Overview - ScienceDirect — The interactions between epigenetics and genetics play a critical role in carcinogenesis and cancer progression through uncontrolled proliferation, cancer heterogeneity and metastasis (Figure 1).
[19] Epigenetic changes in cancer - PMC — A strong selling point for epigenetic cancer research is the fact that epigenetically inactivated genes can conceivably be reactivated with the right drugs, while genetic changes are irreversible.
[20] Epigenetic modifications: Key players in cancer heterogeneity and drug ... — In addition, the interplay between genetic and epigenetic alterations adds another layer of complexity. How these alterations interact and influence each other and collectively shape the tumor landscape and response to therapy is a significant question that remains largely unexplored. ... Ahmed Y.W., et al. Epigenetic tumor heterogeneity in the
[21] An Epigenetic Perspective on Intra-Tumour Heterogeneity: Novel Insights ... — Cancer is a group of heterogeneous diseases that results from the occurrence of genetic alterations combined with epigenetic changes and environmental stimuli that increase cancer cell plasticity. Indeed, multiple cancer cell populations coexist within the same tumour, favouring cancer progression and metastatic dissemination as well as drug
[22] Epigenetic heterogeneity in cancer - Biomarker Research — Complete understanding of genetic and epigenetic heterogeneity may assist in designing combinations of targeted therapies based on molecular information extracted from individual tumors. ... Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer
[42] Life history dynamics of evolving tumors: insights into task ... — Current investigations of tumor evolution echo earlier debates between biologists. These include the role of non-Darwinian mechanisms, the contribution of neutral evolution, and life history dynamics. The trade-off between proliferation and metastasis is the most well-studied application of life history theory to cancer evolution.
[43] Evolution of Cancer Pharmacological Treatments at the Turn of the Third ... — The reduction in mortality rates can be easily associated with the continuous progress in the medical and pharmacological fields that has allowed to reduce the cancer deaths, thanks to the recent introduction in therapy of more effective drugs and therapeutic approaches (Soneji et al., 2014; Miller et al., 2016). The first historical and scientific records of tumors in humans date back to the Egyptian period, around 3000 B.C., and refer to the writings contained in a papyrus found by Edwin Smith, in which a case of breast cancer and the surgical treatment adopted were described (Breasted, 1930; Sanchez and Meltzer, 2012). 10.1016/j.it.2015.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar] Cancer 2, 877–883. J. Cancer Res. Ther. Cancer 12, 237–251. Cancer 8, 249–258.
[50] The road from Rous sarcoma virus to precision medicine - PMC — As part of JEM's 125th anniversary celebration, Olivier Elemento discusses Peyton Rous's discovery in 1911 that led to the identification of virus-inducing tumors, oncogene discovery, and the development of modern tumor biology.. Abstract. In 1911, more than a century ago, Peyton Rous described a curious observation, later explained by a virus named for him that led to the discovery of
[52] PDF — cer. The spindle-cell sarcoma Rous observed in the new bird was indistin-guishable from the tumor in the original hen. Rous had found that a filterable agent, in modern parlance, a virus, could transmit cancer. 2 It remains a seminal discovery of 20th century biology. Not many were convinced in Rous's day. The scientific establish-
[53] 100 years of Rous sarcoma virus - PubMed — The discovery of Rous sarcoma virus, which was reported by Peyton Rous in the Journal of Experimental Medicine 100 years ago, opened the field of tumor virology. It showed that some cancers have infectious etiology, led to the discovery of oncogenes, and laid the foundation for the molecular mechani …
[58] Cancer biomarkers: Emerging trends and clinical implications for ... — Cancer biomarkers have transformed oncology, enabling treatments tailored to each tumor's unique profile. This review highlights the field's progress due to advancements in understanding cancer biology, testing methods, and understanding of the immune microenvironment to advance precision oncology for improved patient outcomes.
[60] Milestones in Cancer Research and Discovery - NCI — FDA approves tamoxifen, an antiestrogen drug originally developed as a birth control treatment, for the treatment of breast cancer. FDA approves trastuzumab, a monoclonal antibody that targets cancer cells that overexpress the HER2 gene, for the treatment of women with HER2-positive metastatic breast cancer. FDA approves sipuleucel-T, a cancer treatment vaccine that is made using a patient's own immune system cells (dendritic cells), for the treatment of metastatic prostate cancer that no longer responds to hormonal therapy. FDA approves ado-trastuzumab emtansine (T-DM1) for the treatment of patients with HER2-positive breast cancer who were previously treated with trastuzumab and/or a taxane drug. NCI and the ECOG-ACRIN Cancer Research Group launch the NCI-MATCH (Molecular Analysis for Therapy Choice) clinical trial to test more than 20 drugs and drug combinations based on molecular analysis of tumors in people with cancer.
[62] Exploring treatment options in cancer: tumor treatment strategies - Nature — The approval of T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, highlighted the resurgence of oncolytic viruses as a cancer treatment modality.19,20 The 2020 s have seen further advancements with the FDA approval of Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations.21 In 2021, the National Comprehensive Cancer Network (NCCN) guidelines highlighted the combination of atezolizumab and bevacizumab as the preferred first-line treatment option for patients with hepatocellular carcinoma (HCC).22 This recommendation underscores the importance of immunotherapy and anti-angiogenic therapy in the frontline management of this aggressive form of cancer, reflecting the evolving landscape of cancer care and the continuous efforts to improve patient outcomes (Fig. 1).
[63] Personalized medicine in oncology: the future is now - PubMed — Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at unique molecular features of cancer cells, and immunotherapeutics modulate the tumour immune response; …
[64] Revolutionizing cancer treatment: the rise of personalized ... — It acknowledges the challenges, including drug resistance and the need for high specificity in certain therapies, while also highlighting the effectiveness of cancer vaccines, modified T-cells, and oncolytic viruses. There are different types of biological therapies for cancer and they include: cancer vaccines, angiogenesis inhibitors, adoptive cell transfer, monoclonal antibodies, immune checkpoint modulators, targeted drug therapy, chimeric antigen receptor (CAR) T-cell therapy, targeted drug therapy and chemotherapy, cytokine therapy, Bacillus Calmette-Guerin therapy, gene therapy, immunoconjugates and oncolytic virus therapy. In this review, we have discussed various biological therapies and their effectiveness in targeting different types of cancers, with a focus on the potential of monoclonal antibodies and adoptive cell transfer in personalized medicine.
[65] The growing role of precision and personalized medicine for cancer ... — Companion diagnostics (CDx) help identify which treatments will be most effective for a specific patient’s tumor, and novel cell therapies are used to target the cancer with minimal damage to healthy tissues, making the PPM model more effective and safer. Recent work has focused on the development of more accurate tumor models (organoids) and harnessing the specificity of the immune system to develop effective cancer vaccines or mAbs. The personalized treatment approach has resulted in improved patient outcomes in terms of response rate and progression-free survival in Phase I clinical trials that selected patients using a specific biomarker versus those that did not174.
[79] A Comprehensive Review of Recent Advancements in Cancer ... - MDPI — The mechanisms involved in immune responses to cancer have been extensively studied for several decades, and considerable attention has been paid to harnessing the immune system's therapeutic potential. Cancer immunotherapy has established itself as a promising new treatment option for a variety of cancer types. Various strategies including cancer vaccines, monoclonal antibodies (mAbs
[81] Exploring treatment options in cancer: tumor treatment strategies — The approval of T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, highlighted the resurgence of oncolytic viruses as a cancer treatment modality.19,20 The 2020 s have seen further advancements with the FDA approval of Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations.21 In 2021, the National Comprehensive Cancer Network (NCCN) guidelines highlighted the combination of atezolizumab and bevacizumab as the preferred first-line treatment option for patients with hepatocellular carcinoma (HCC).22 This recommendation underscores the importance of immunotherapy and anti-angiogenic therapy in the frontline management of this aggressive form of cancer, reflecting the evolving landscape of cancer care and the continuous efforts to improve patient outcomes (Fig. 1).
[82] Tumor biomarkers for diagnosis, prognosis and targeted therapy — Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Moreover, several PCR assays approved by the FDA are used for the diagnosis of KRAS mutation status in formalin-fixed paraffin-embedded tissue, thereby guiding anti-EGFR antibody treatment for metastatic CRC.87 Similarly, qPCR assays are effective in the detection of MRD in leukemia, such as the quantification of BCR-ABL-positive cells post-induction chemotherapy/transplantation in acute lymphoblastic leukemia (ALL).85 PCR technology is also widely used to detect abnormal genes and abnormal mRNA amplification in tumors, such as MYCN amplification in neuroblastoma.88 Ligand-targeted PCR is essential for the detection of folate receptor-positive circulating tumor cells as a potential diagnostic biomarker in pancreatic cancer.89
[89] Current advances in immunotherapy for cancer - ScienceDirect — Search ScienceDirect open access Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function. Previous article in issue Next article in issue Recommended articles No articles found. Article Metrics View article metrics For all open access content, the Creative Commons licensing terms apply.
[92] Personalized medicine: Clinical oncology on molecular view of treatment ... — Core Tip: This review emphasizes the importance of precision medicine in cancer treatment, highlighting the role of molecular biology in identifying specific genetic markers for more accurate prognosis and targeted therapies. The integration of biomarkers into clinical practice not only revolutionizes the approach to cancer, allowing for more precise and stratified diagnoses but also paves the way for personalized and targeted therapies, promoting significant advancements in cancer treatment. Furthermore, recent advances in precision medicine have considerably expanded our understanding of the genetic aspects surrounding breast cancer, enabling a more personalized and effective approach in identifying specific therapeutic targets, representing a significant milestone in oncology. To complement, Table 1 below presents information provided by precision medicine specific to some molecular subtypes of cancer, genomic mutations, biomarkers in exosomes, and treatment options[50-55].
[93] Mechanism of Action of Immunotherapy - ScienceDirect — The goal of cancer immunotherapy is to boost or restore the ability of the immune system to detect and destroy cancer cells by overcoming the mechanisms by which tumors evade and suppress the immune response, 16 in essence to shift the equilibrium back in favor of immune protection.
[95] Immunotherapy combination approaches: mechanisms, biomarkers and ... — Advertisement View all journals Search Log in Explore content About the journal Publish with us Subscribe Sign up for alerts RSS feed nature nature reviews immunology review articles article Review Article Published: 06 December 2023 Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations Lisa H. Butterfield ORCID: orcid.org/0000-0002-3439-98441 & Yana G. Najjar ORCID: orcid.org/0000-0002-0138-16642 Nature Reviews Immunology volume 24, pages 399–416 (2024)Cite this article 15k Accesses 38 Altmetric Metrics details Subjects Biomarkers Immunology Abstract The approval of the first immune checkpoint inhibitors provided a paradigm shift for the treatment of malignancies across a broad range of indications. Whereas initially, single-agent immune checkpoint inhibition was used, increasing numbers of patients are now treated with combination immune checkpoint blockade, where non-redundant mechanisms of action of the individual agents generally lead to higher response rates. Furthermore, immune checkpoint therapy has been combined with various other therapeutic modalities, including chemotherapy, radiotherapy and other immunotherapeutics such as vaccines, adoptive cellular therapies, cytokines and others, in an effort to maximize clinical efficacy. Here, we present the rationale for combination therapies and discuss clinical data from clinical trials across the immuno-oncology spectrum.
[105] Tumor initiation and early tumorigenesis: molecular mechanisms and ... — Tumorigenesis is a multistep process, with oncogenic mutations in a normal cell conferring clonal advantage as the initial event. However, despite pervasive somatic mutations and clonal expansion in normal tissues, their transformation into cancer remains a rare event, indicating the presence of add …
[106] Tumor initiation and early tumorigenesis: molecular mechanisms and ... — Subsequently, the first proto-oncogene, RAS, and tumor suppressor gene, RB1, were cloned in the early 1980s.11,12,13 Following this, a significant number of these two classes of cancer genes were identified, accompanied by discovery of other forms of variations, including copy number alterations, translocations and promoter hypermethylation.14 In the middle of 2000s, benefiting from next-generation sequencing, cancer genomics flourished and promoted the launch of large-scale tumor sequencing initiatives, such as The Cancer Genome Atlas (TCGA) in 2006 and the International Cancer Genome Consortium (ICGC) in 2007.15 The TCGA consortium published its Pan-Cancer Analysis of Whole Genomes (PCAWG) data in 2020, which contained the whole genomic sequencing data of 38 tumor types from more than 2800 patients, largely expanding our understanding of cancer genomics.16 According to the influence in cancer development, mutations can be categorized as driver mutations and passenger mutations.
[107] Tumor initiation and early tumorigenesis: molecular mechanisms and ... — Key processes required for early tumorigenesis. The identities of transformed cells are the result of the combined influence of intrinsic genetic and epigenetic profiles and external signaling. These factors collectively activate oncogenic pathways and remodel the microenvironment (Fig. 3). Consequently, there are not only cell-autonomous
[108] Inflammation: A key process in skin tumorigenesis - PMC — Abstract. The extremely delicate shift from an inflammatory process to tumorigenesis is a field of major scientific interest. While the inflammation induced by environmental agents has well known underlying mechanisms, less is known concerning the oncogenic changes that follow an inflammatory chronic status in the tissue microenvironment that can lead to pro-tumorigenic processes.
[110] Ras Signaling: Pathways, Mutations, and Tumor Onset — By influencing the TGF-β pathway, RAS enhances its oncogenic potential and contributes to the complexity of therapeutic interventions. Oncogenic Mutations And Tumor Onset Mutations in RAS genes are among the most common alterations found in human cancers, significantly contributing to tumor onset and progression.
[111] The role of RAS oncogenes in controlling epithelial mechanics — Mutations in RAS are key oncogenic drivers and therapeutic targets. ... some of which are likely to influence the ability of cells to undergo migration and invasion. Figure 1. Open in a new tab ... Such functions in the context of epithelia may explain the role played by the Rho-ROCK pathway in RAS-driven tumorigenesis and metastasis, making it
[113] Oncogenic Signaling Pathways in The Cancer Genome Atlas - Cell Press — Several important signaling pathways have been identified as frequently genetically altered in cancer, including the RTK/RAS/MAP-Kinase (hereafter also called RTK-RAS for brevity) pathway, PI3K/Akt signaling, and others (Vogelstein and Kinzler, 2004).Members of these pathways and their interactions have been captured in a number of pathway databases, such as Pathway Commons (Cerami et al
[114] PDF — By tailoring healthcare to the unique genetic makeup of each patient, personalized medicine holds the promise of more effective, targeted, and precise interventions, minimizing adverse effects and optimizing therapeutic outcomes. Unlike the traditional one-size-fits-all approach to healthcare, personalized medicine considers a patient’s genetic profile, lifestyle, and environmental factors to create customized treatment plans. For patients with rare genetic disorders, personalized medicine offers new hope for diagnosis and treatment. The integration of personalized medicine into routine clinical practice will likely lead to more precise and effective healthcare, reducing the burden of disease and improving patient outcomes. By tailoring diagnosis and treatment to a patient’s genetic profile, personalized medicine offers the potential for more effective and precise interventions, ultimately improving patient outcomes.
[115] PDF — However, the integration of personalized medicine into standard clinical practice poses challenges, including the need for extensive education of healthcare providers, concerns about genetic data privacy, and the high costs associated with genetic testing and analysis.
[116] (PDF) The Role of Genetics in Personalized Medicine: Advancements ... — (PDF) The Role of Genetics in Personalized Medicine: Advancements, Challenges, and Ethical Considerations The Role of Genetics in Personalized Medicine: Advancements, Challenges, and Ethical Considerations This article explores the advancements, challenges, and ethical considerations associated with the integration of genetics into personalized medicine. Ethical considerations, including genetic discrimination, privacy and confidentiality, informed consent, and equitable distribution of resources, are crucial in the implementation of personalized medicine. Collaboration among researchers, healthcare providers, policymakers, and ethicists is necessary to ensure the responsible and ethical use of genetic information, safeguard patient privacy, and promote equitable access to personalized medicine resources. By navigating these advancements, overcoming challenges, and addressing ethical considerations, personalized medicine can revolutionize healthcare, providing tailored and effective treatments for individuals based on their unique genetic characteristics.
[117] Personalized Medicine: Tailoring Diagnosis to Individual Genetic Profiles — Personalized medicine represents a paradigm shift in healthcare, moving away from a one-size-fits-all approach to a more individualized model of care. By tailoring diagnosis and treatment to a patient's genetic profile, personalized medicine offers the potential for more effective and precise interventions, ultimately improving patient outcomes.
[118] Deciphering functional tumor-immune crosstalk through highly ... — The tumor microenvironment (TME) is a complex ecosystem where cancer cells dynamically interact with diverse non-malignant cells, including immune cells, fibroblasts, and endothelial cells, as well as the extracellular matrix. 1 These intricate interactions shape cancer progression and therapy response. 2 In particular, crosstalk between cancer cells and immune cells within the TME plays a
[119] The m6A revolution: transforming tumor immunity and enhancing ... — MDSCs. MDSCs represent a heterogeneous population of immune cells that play a pivotal role in cancer progression by establishing an immunosuppressive tumor microenvironment .These cells are implicated in various malignancies, including lung, ovarian, endometrial, and liver cancers, where they facilitate immune evasion, promote tumor growth, and contribute to treatment resistance .
[120] Tumor microenvironment: recent advances in understanding and its role ... — Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies | Medical Oncology Oncogene-driven changes in tumor cell metabolism can impact the TME to limit immune responses and present barriers to cancer therapy. Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic/photothermal/chemodynamic treatment of cervical cancer. Stromal cells in tumor microenvironment and breast cancer. https://doi.org/10.3390/cancers16030626. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Peng S, Wang H, Xin Y, Zhao W, Zhan M, Li J, et al. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. https://doi.org/10.3390/cancers14133170.
[121] The tumor microenvironment: Current Biology - Cell Press — The composition of the tumor microenvironment varies between tumor types, but hallmark features include immune cells, stromal cells, blood vessels, and extracellular matrix. It is believed that the "tumor microenvironment is not just a silent bystander, but rather an active promoter of cancer progression" ( Truffi et al. , 2020 ).
[122] The tumor microenvironment - ScienceDirect — Immune cells are critical components of the tumor microenvironment. Depending on the context, a dichotomy exists in the relationship between immune cells and the tumor microenvironment: immune cells can either suppress tumor growth or promote it (Figure 1).Persistent inflammation due to chronic infection is a common mechanism underlying tumor formation in several types of cancer, including
[140] Chronic Inflammation and Cytokines in the Tumor Microenvironment — Inflammation can increase the risk of cancer by providing bioactive molecules from cells infiltrating the tumor microenvironment, including cytokines; growth factors; chemokines that maintain a sustained proliferative rate; cell survival signals to avoid apoptosis; proangiogenic factors; and extracellular matrix-modifying enzymes such as
[149] A guide to cancer genomics — An overview of cancer biology. Cancer genomics sequencing options. Over the last decade, the rapid development of next-generation sequencing (NGS) approaches has vastly altered the cancer genomics landscape, providing researchers with the ability to assess multiple genes simultaneously. In this short time, NGS has enabled a deeper understanding
[150] Accelerating the understanding of cancer biology through the lens of ... — The initial mission of cancer genomics was to identify all cancer driver genes, primarily with the aid of next-generation sequencing (NGS)-based technologies. 1 Cancer genomics studies have evolved from investigations of a handful of genes or tumors to large-scale, whole-genome, multi-omics and pan-cancer analyses (Figure 1B), as exemplified by The Cancer Genome Atlas (TCGA) 2 and
[151] Cancer genome research and precision medicine - NCI — By characterizing not only the DNA, but also gene expression, proteins, and many other molecular features of cancer, researchers can identify key changes that may cause the disease. By taking advantage of new types of data, improvements in data quality, and reductions in cost for sequencing, researchers are gaining a fuller understanding of cancer. Once cancer-causing changes are identified, scientists can gain a better understanding of the molecular basis of cancer growth, metastasis, and drug resistance. Importance of Cancer Genomics in Precision Cancer Medicine Genomic information about cancer is leading to better diagnoses and treatment strategies that are tailored to patients’ tumors, an approach called precision medicine. Using the genetic changes in a patient’s tumor to determine their treatment is known as precision medicine.
[152] Cancer Biology, Epidemiology, and Treatment in the 21st Century ... — Cancer is a disease that begins with genetic and epigenetic alterations occurring in specific cells, some of which can spread and migrate to other tissues.4 Although the biological processes affected in carcinogenesis and the evolution of neoplasms are many and widely different, we will focus on 4 aspects that are particularly relevant in tumor biology: genomic and epigenomic alterations that lead to cell transformation, the cells where these changes occur, and the processes of invasion and metastasis that, to an important degree, determine tumor aggressiveness. The genomics of cancer can be defined as the study of the complete sequence of DNA and its expression in tumor cells. Cancer.
[153] Existing and Emerging Technologies for Tumor Genomic Profiling — Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics and tumor biology. In parallel, information gleaned from these studies on driver cancer gene alterations—mutations, copy number alterations,
[154] Integrating cancer genomic data into electronic health records — Improved integration of cancer genomic data with EHR systems will help guide clinician decision making, support secondary uses, and ultimately improve patient care within oncology clinics.
[155] Interpreting and integrating genomic tests results in clinical cancer ... — We provide an overview on genomic biomarkers and their clinical relevance for therapeutic selection in patients with advanced solid tumors, describe assay technologies and sequencing processes, and offer practical advice on how to interpret and integrate molecular profiling into clinical decision making.
[156] Precision Oncology Program (POP), an observational study ... - BMJ Open — This program uses patient-matched clinicogenomic data and spatial single-cell proteomics analysis to support profiling-driven decision-making for patients with cancer at the Molecular Tumor Board.
[157] Large-Scale Genomic Analysis Improves Outcomes in 20 Cancer Types — Researchers at Genentech and Stanford University have found 776 genomic alterations linked to survival outcomes across 20 cancer types with specific immunotherapies, chemotherapies, or targeted therapies. The team carried out a comprehensive analysis of 78,287 U.S. cancer patients with detailed somatic mutation profiling integrated with treatment and outcomes data extracted from electronic
[158] Pharmacogenomics and Personalized Medicine - PMC — These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastractures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics. The study of genetics has been widely applied in precision medicine, and one of the emerging applications is pharmacogenomics-informed pharmacotherapy, tailoring drug selection and dosing to the patient’s genetic features. In conclusion, the studies collected in this volume underline the potential of innovative molecular approaches, including multilocus genotyping, sequencing of rare variants and epigenetic features, in identifying genetic determinants of interindividual variability in the effects of drugs in several important clinical settings, including chemotherapy of breast cancer and leukemia and anticoagulant therapy for cardiovascular diseases.
[159] The emergence of cancer genomics in diagnosis and precision medicine ... — The resulting data expedited the discovery of new drivers, pathways and hallmarks of cancer biology, as well as novel drug targets, and established crucial links between the cancer genome and
[160] Personalized cancer medicine: next steps in the genomic era — Personalized cancer medicine: next steps in the genomic era - PMC In this special issue of Cellular Oncology some key recent developments and points of concern in the field of personalized cancer care are reviewed, including which steps still need to be taken before the final implementation of personalized cancer medicine becomes a clinical reality. While tremendous efforts in recent years have paved the way for the next step in personalized biology-driven cancer medicine in the genomic era, major challenges are still lying ahead of us. Cell Oncol 35, 139–147 (2012) [DOI] [PMC free article] [PubMed] 9.L.H. Mammatas, H.M. Verheul, N.H. Hendrikse, et al., Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.
[161] The Cancer Genome Atlas: Insights and Implications — The impact of The Cancer Genome Atlas (TCGA) on cancer research cannot be overstated. This monumental project has fundamentally reshaped our understanding of cancer on a molecular level. ... For instance, the identification of specific mutations in genes like TP53 or BRCA allows for more targeted therapies, potentially improving patient
[162] Oncogenic Signaling Pathways in The Cancer Genome Atlas - Cell Press — An integrated analysis of genetic alterations in 10 signaling pathways in >9,000 tumors profiled by TCGA highlights significant representation of individual and co-occurring actionable alterations in these pathways, suggesting opportunities for targeted and combination therapies.
[163] Precision oncology: Using cancer genomics for targeted therapy ... — Precision oncology: Using cancer genomics for targeted therapy advancements - ScienceDirect Precision oncology: Using cancer genomics for targeted therapy advancements The integration of precision medicine with cancer genomics emphasizes the significance of utilizing genetic data in treatment decision-making, enabling personalized care and enhancing patient outcomes. Cancer genomics has revolutionized our understanding of tumor biology by leveraging genetic data for personalized therapies . This review explores the advancements in cancer genomics, its impact on treatment strategies, and the challenges in clinical application. Cancer genomics has shifted from histopathology-based classifications to a more detailed understanding of tumors through genetic analysis . The field of cancer genomics is expanding, but the transition from genetic discovery to therapeutic applications remains challenging.
[164] Tumor microenvironment complexity and therapeutic implications at a ... — Tumor microenvironment complexity and therapeutic implications at a glance | Cell Communication and Signaling | Full Text Search all BMC articles Tumor microenvironment complexity and therapeutic implications at a glance Tumor microenvironment complexity and therapeutic implications at a glance The dynamic interactions of cancer cells with their microenvironment consisting of stromal cells (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to stimulate the heterogeneity of cancer cell, clonal evolution and to increase the multidrug resistance ending in cancer cell progression and metastasis. Understanding the underlying cellular and molecular mechanisms governing these interactions can be used as a novel strategy to indirectly disrupt cancer cell interplay and contribute to the development of efficient and safe therapeutic strategies to fight cancer.
[165] Unraveling the tumor microenvironment: Insights into cancer metastasis ... — Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies - ScienceDirect Dynamic TME Interactions: Cancer cells and the tumor microenvironment (TME) have an intricate relationship that impacts cancer progression and therapeutic responses. This comprehensive review delves into the pivotal role of the tumor microenvironment (TME) in cancer metastasis and therapeutic response, offering fresh insights into the intricate interplay between cancer cells and their surrounding milieu. Moreover, it investigates innovative therapeutic approaches aimed at targeting the TME, including stromal reprogramming, immune microenvironment modulation, extracellular matrix (ECM)-targeting agents, and personalized medicine strategies, highlighting their potential to augment treatment outcomes. Next article in issue No articles found. For all open access content, the relevant licensing terms apply.
[166] Revealing the contribution of somatic gene mutations to shaping tumor ... — Somatic gene mutations were found not only to elicit adaptive immunity but also to influence the composition of tumor immune microenvironment and various processes of antitumor immunity. However, due to an incomplete view of associations between gene mutations and immunophenotypes, how tumor cells shape the immune microenvironment and further
[189] Exploring treatment options in cancer: tumor treatment strategies — The approval of T-VEC in 2015 and Delytact in 2021 for melanoma and malignant glioma, respectively, highlighted the resurgence of oncolytic viruses as a cancer treatment modality.19,20 The 2020 s have seen further advancements with the FDA approval of Sotorasib, the first small molecule inhibitor targeting specific KRAS gene mutations.21 In 2021, the National Comprehensive Cancer Network (NCCN) guidelines highlighted the combination of atezolizumab and bevacizumab as the preferred first-line treatment option for patients with hepatocellular carcinoma (HCC).22 This recommendation underscores the importance of immunotherapy and anti-angiogenic therapy in the frontline management of this aggressive form of cancer, reflecting the evolving landscape of cancer care and the continuous efforts to improve patient outcomes (Fig. 1).
[192] Exploring treatment options in cancer: Tumor treatment strategies — Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. The new millennium brought targeted therapies for non-small cell lung cancer with drugs like Gefitinib and Erlotinib, and the first anti-angiogenic drug, Bevacizumab, which targeted tumor blood supply. ADCs exert their therapeutic effects through a process that begins with the specific binding of the antibody component of the ADC to antigens on the surface of tumor cells. Once in the body, CAR-NK cells utilize their CAR to recognize and bind to specific tumor antigens, leading to their activation and the subsequent release of cytotoxic granules and cytokines to eliminate cancer cells.
[196] Unlocking the code: The role of molecular and genetic profiling in ... — Unlocking the code: The role of molecular and genetic profiling in revolutionizing glioblastoma treatment - ScienceDirect Emerging therapeutic approaches aim to address these challenges, including the use of immunotherapies such as immune checkpoint inhibitors and CAR T-cell therapies, which target specific tumor antigens but face hurdles due to the immunosuppressive TME. Additionally, novel strategies like biopolymer-based interstitial therapies, focused ultrasound for blood-brain barrier disruption, and nanoparticle-based drug delivery systems show promise in enhancing the efficacy and precision of GBM treatments. This review explores the evolving landscape of GBM therapy, emphasizing the importance of personalized medicine through molecular profiling, the potential of combination therapies, and the need for innovative approaches to overcome therapeutic resistance. For all open access content, the relevant licensing terms apply.
[197] From Genomic Exploration to Personalized Treatment: Next-Generation ... — NGS offers comprehensive cancer profiling, which enables clinicians and researchers to better understand the molecular basis of cancer and to tailor treatment strategies accordingly. Targeted therapies based on genomic alterations identified through NGS have shown promise in improving patient outcomes across various cancer types, circumventing
[227] A video intervention to improve patient understanding of tumor genomic ... — Introduction: Tumor genomic testing (TGT) is standard-of-care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is frequently omitted. The purpose of this study was to evaluate the impact of a concise 4 min video for patient education prior to TGT.
[228] Cancer biomarkers: Emerging trends and clinical implications for ... — Cancer biomarkers have transformed oncology, enabling treatments tailored to each tumor's unique profile. This review highlights the field's progress due to advancements in understanding cancer biology, testing methods, and understanding of the immune microenvironment to advance precision oncology for improved patient outcomes.
[229] Towards a more precise future for oncology - PMC — This refined patient matching is enabled by our growing understanding of the interaction between specific molecular alterations and the histologic and broader genomic context of the tumor as well as our improved ability to recognize oncogenic drivers among a much larger number of variants of unknown significance in individual tumors.
[230] Accelerating the understanding of cancer biology through the lens of ... — In 2008, the first whole-genome sequencing of human cancer was performed on acute myeloid leukemia, 11 and in 2010, whole genomes of solid tumors from a patient with lung cancer (LC) 12 and a patient with breast cancer (BC) 13 were sequenced, identifying somatic variations in both protein-coding and non-coding regions, including RNA genes
[246] Personalising cancer treatment and diagnosis through genomic medicine ... — We will also explore how patients, including potential and past patients, together with others affected by cancer in their families, act as advocates for personalised genomic medicine, particularly in relation to access to trials and costly experimental drugs, as part of these anticipatory regimes (Adams et al. This involves patients and their advocates in a range of activities to understand, source and secure particular treatments or combinations of treatments through being on trial, as access to personalised therapies becomes an expected part of the patient journey, reinforced by the promise of personalised cancer medicine.
[247] Nursing Implications of Personalized and Precision Medicine — The implications in personalized and precision cancer nursing care include interpretation and clinical use of novel and personalized information including genetic testing; patient advocacy and support throughout testing, anticipation of results and treatment; ongoing chronic monitoring; and support for patient decision-making.
[248] PDF — Received: 04 October, 2024, Manuscript No. cmcr-24-158249; Editor assigned: 05 October, 2024, Pre QC No. P-158249; Reviewed: 17 October, 2024, QC No. Q-158249; Revised: 22 October, 2024, Manuscript No. R-158249; Published: 29 October, 2024, DOI: 10.37421/2684-4915.2024.8.339 The Role of Personalized Medicine in Cancer Treatment Dangel Kach* Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland Introduction Personalized medicine, also known as precision medicine, is an innovative approach to healthcare that tailors medical treatment to the individual characteristics of each patient, particularly in the treatment of cancer. By analyzing these biomarkers, doctors can gain a deeper understanding of a patient's cancer at a molecular level, enabling them to choose therapies that specifically target the genetic mutations or abnormal signaling pathways driving the disease.
[249] The growing role of precision and personalized medicine for cancer ... — Companion diagnostics (CDx) help identify which treatments will be most effective for a specific patient’s tumor, and novel cell therapies are used to target the cancer with minimal damage to healthy tissues, making the PPM model more effective and safer. Recent work has focused on the development of more accurate tumor models (organoids) and harnessing the specificity of the immune system to develop effective cancer vaccines or mAbs. The personalized treatment approach has resulted in improved patient outcomes in terms of response rate and progression-free survival in Phase I clinical trials that selected patients using a specific biomarker versus those that did not174.